Ammonium Molybdate Injection
Name: Ammonium Molybdate Injection
- Ammonium Molybdate Injection injection
- Ammonium Molybdate Injection 15 mg
- Ammonium Molybdate Injection ammonium molybdate injection dosage
- Ammonium Molybdate Injection dosage
- Ammonium Molybdate Injection drug
Indications and Usage for Ammonium Molybdate Injection
Ammonium Molybdate Injection, USP is indicated for use as a supplement to TPN solutions. Administration of Molybdenum in TPN solutions helps to prevent depletion of endogenous stores and subsequent deficiency symptoms.
- Ammonium Molybdate Injection, USP should not be given undiluted by direct injection into a peripheral vein because of the potential of infusion phlebitis.
- Ammonium Molybdate Injection, USP without copper supplementation should not be given to copper-deficient patients.
In humans, consumption of food grown in molybdeniferous soils, estimated to provide 10 to 15 mg molybdenum/day, has been associated with goutlike syndrome with increased blood levels of molybdenum, uric acid, and xanthine oxidase.
In animals, cattle grazing on molybdeniferous pasture have been reported to develop molybdenosis known as “teart” or “peat scours”. The condition is characterized by diarrhea, bone deformities, growth failure, alopecia and anemia. Similar conditions except diarrhea, have been experimentally induced in rat, chicken, and sheep maintained on high dietary Molybdenum intakes.
No information on the treatment of molybdenosis in humans is available. Among animals, treatment with copper, sulfate ions, and tungsten has been reported to enhance excretion of molybdenum thus imparting protection against molybdenosis. The sulfur-containing amino acids, methionine and cysteine, have also been reported to afford limited protection in molybdenosis in sheep.
Ammonium Molybdate Injection Dosage and Administration
Ammonium Molybdate Injection, USP provides 25 mcg molybdenum/mL. For metabolically stable adults receiving TPN, the suggested additive dosage level is 20 to 120 mcg molybdenum/day. For pediatric patients, the additive dosage level should be calculated by extrapolation.
In an adult, molybdenum deficiency state resulting from prolonged TPN support, intravenous administration of molybdenum as ammonium molybdate at 163 mcg/day for 21 days has been reported to reverse deficiency symptoms without toxicity.
Aseptic addition of Ammonium Molybdate Injection, USP to TPN solutions under a laminar flow hood is recommended. Molybdenum is physically compatible with the electrolytes and other trace elements usually present in amino acid/dextrose solutions used for TPN. Monitoring of sulfur and purine metabolism is suggested as a guideline. Since copper and molybdenum are antagonistic to each other, frequent monitoring of blood copper levels should be carried out during molybdenum TPN supplementation.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
How is Ammonium Molybdate Injection Supplied
Ammonium Molybdate Injection, USP (molybdenum 25 mcg/mL)
NDC 0517-6610-25 10 mL Single Dose Vial packed in boxes of 25
Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) (See USP Controlled Room Temperature).
AMERICAN REGENT, INC.
SHIRLEY, NY 11967
Package label.principal display panel
PRINCIPAL DISPLAY PANEL – 10 mL Carton
Molybdenum 250 mcg/10 mL
Trace Element Additive
25 x 10 mL SINGLE DOSE VIALS
FOR INTRAVENOUS USE AFTER DILUTION
Each mL contains: Ammonium Molybdate (Tetrahydrate) 46 mcg, Water for Injection q.s.
pH adjusted with Ammonium Hydroxide and/or Hydrochloric Acid. Sterile, nonpyrogenic.
WARNING: DISCARD UNUSED PORTION. Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) (See USP Controlled Room Temperature).
Directions for Use: See Package Insert.
SHIRLEY, NY 11967
|AMMONIUM MOLYBDATE |
Ammonium Molybdate Injection, solution
|Labeler - American Regent, Inc. (622781813)|